LAWRENCE, EVANS & CO., LLC

Investment Banking | Healthcare Finance | Consulting

Healthcare Weekly News and Deals – November 28th, 2025

1. **Patient Square Capital completes $2.6 billion take-private acquisition of Premier, Inc (NASD: PINC), paying $28.25 per share in all-cash deal**

   The transaction removes Premier from public markets, with its common stock ceasing trading and being delisted from Nasdaq as of November 25, 2025. As a wholly owned portfolio company, Premier will continue providing data analytics, supply chain solutions, collaboratives, and consulting services that support providers, suppliers, payers, and policymakers in improving healthcare quality and cost. Patient Square, which manages more than $15 billion in healthcare-focused assets, plans to leverage its sector expertise and capital to help Premier accelerate technology-driven offerings that enhance patient outcomes and community health. (Link)

2. **Bruker Corporation (NASD: BRKR) acquires AST Revolution to advance WAVE and Arc rapid antimicrobial susceptibility testing technologies and expand clinical diagnostics portfolio**

   The transaction transfers a newly launched in vitro diagnostics platform built around rapid antimicrobial susceptibility testing systems originally acquired from Accelerate Diagnostics' assets in a Chapter 11 process. Indaba's backing enabled AST Revolution to stabilize operations, advance product development, and position the WAVE and Arc systems as a standalone, leadership-ready rapid AST offering. Company leaders highlighted the collaborative effort that rebuilt the technology and expressed confidence that Bruker's scale, market reach, and diagnostics expertise will accelerate delivery of faster, actionable AST results for clinicians and patients. (Link)

3. **MDI NetworX acquires Cobalt MedPlans (Clarity Performance Solutions) from Cobalt Health Solutions, a Blue Cross and Blue Shield of Kansas City Subsidiary, to Expand U.S. Payer Services and Deploy InsightPro AI Platform**

   The deal brings about 250 U.S. employees into MDI, increasing its global workforce to more than 7,500 and adding operations centers in Overland Park and Fort Scott, Kansas, for a total of four domestic delivery sites alongside international centers. MDI will invest in technology, process optimization, and workforce enablement, anchored by its AI-enabled InsightPro SaaS platform to automate workflows, enhance analytics, and improve quality oversight. The combined organization aims to offer end-to-end operational solutions that help healthcare payers scale, boost service levels, and better control administrative costs through flexible, compliant service models. (Link)

4. **US Fertility partners with L Catterton and Amulet Capital Partners in new co-lead investor structure to expand access to advanced reproductive care across the U.S.**

   The revised ownership keeps physician partners as substantial owners while adding fresh capital and consumer-health expertise to scale clinics, IVF labs, and research programs. US Fertility, formed with Amulet in 2020, now operates more than 120 clinic and laboratory locations, serving over 60,000 new patients each year and having supported more than 400,000 individuals and couples through assisted reproductive technology. The partnership is intended to broaden access to IVF, IUI, genetic testing, and related services while maintaining a physician-led, patient-centered model. (Link)

5. **MedEdge Holdings launches with $450 million management-led buyout to integrate Abyrx's biomaterials portfolio and Kairuku's surgical SaaS platform**

   The new holding company will combine a biomaterials portfolio with commercial operations software to simplify how hospitals and surgical teams source products, manage inventory, and coordinate case support. It plans to use profitable existing operations and fresh capital to acquire and in-license additional commercial-stage surgical technologies, targeting 10–15 companies with strong margins and early market traction. The structure is designed to lower administrative complexity in operating rooms while expanding access to next-generation biomaterials and SaaS tools. Legal advisory support was provided for the transaction, while individual company valuations were kept confidential. (Link)

6. **FluidAI Medical acquires Emmetros Limited, developer of SparxConnect, to strengthen AI-driven Stream Inara patient engagement**

   FluidAI is deepening its focus on postoperative monitoring and patient communication by integrating Emmetros' collaboration technology into its Stream Inara solution, which guides patients before surgery and supports them throughout home recovery. The combined capabilities help hospitals enable earlier discharge while maintaining visibility into patient outcomes and capturing patient-reported data across the surgical journey. This integration complements FluidAI's Origin monitoring device, Stream Care surgical expert suite, and broader RISE program, giving health systems tools to increase throughput, optimize bed use, and personalize data-driven recovery pathways. (Link)

7. **Innova Therapeutics acquires Enci Therapeutics to advance IVT-8086, a first-in-class monoclonal antibody targeting SFRP2 in solid and hematologic cancers**

   The transaction consolidates ownership of IVT-8086 under Innova, allowing focused development of this antibody, which blocks the SFRP2-driven non-canonical Wnt/Ca2+ pathway involved in angiogenesis, tumour growth, immune evasion, and metastasis. Preclinical data show reduced tumour burden in primary and metastatic models, modulation of tumour-infiltrating lymphocytes, inhibition of angiogenesis, and repolarization of tumour-associated macrophages. Because SFRP2 is widely expressed and correlates with outcomes, IVT-8086 is being positioned for use alone or with immune checkpoint inhibitors, alongside a companion diagnostic assay for detection, prognosis, and recurrence risk. (Link)

8. **MiCare Path acquires Compwell, LLC to accelerate national expansion of AI-powered virtual care platform**

   The company now supports tens of thousands of patients across multiple specialties via a reimbursable virtual care platform that powers RPM, RTM, CCM, and PCM programs for clinics and health systems. New capital and the Compwell integration will expand clinical programs, deepen health system partnerships, and speed AI innovation on MiCare Path's FDA-registered software to automate workflows and enhance proactive, personalized care. With more than 40 employees, MiCare Path promotes a “health-digital” model that augments clinician–patient relationships while extending care into patients’ daily lives beyond office visits. (Link)

9. **Brown’s Medical Imaging and Prestige Medical Imaging merge to expand nationwide, multi-vendor medical imaging service capabilities**

   The unified organization operates under the Brown’s Medical Imaging brand, significantly broadening its U.S. footprint and emphasizing vendor-agnostic service backed by industry-leading uptime guarantees and service response commitments. With more than 150 field-based service engineers, it offers rapid remote and onsite support to keep imaging operations efficient and dependable while anchoring its model on customer-first partnership, end-to-end service, and a strong family legacy. The merger coincides with the promotions of Zach Brown to COO and Joe Scavo to CCO, supporting the company’s next phase of growth as it celebrates 30 years in medical imaging. (Link)

   AleraCare, backed by Hildred Capital Management, to merge with Pure Healthcare to Form National Platform for Ambulatory Infusion and Specialty Care

   The combined organization spans 77 ambulatory infusion centers across 14 states, adding growing home and alternate-site services for patients with complex chronic and autoimmune conditions. It offers a broad therapy portfolio across immunology, neurology, gastroenterology, rheumatology, ophthalmology, and other high-acuity disease areas, supported by a single contracting and operational platform for payors, providers, and biopharma. AI-enabled tools streamline scheduling, benefits verification, and real-time outcomes tracking, while a mission-driven workforce focuses on safety, compassion, and uninterrupted care as branding and system integrations progress. (Link)

10. **Walgreens acquires Fruth Pharmacy after years of PBM reimbursement pressure on regional chain**

    Fruth Pharmacy, a family-owned operator serving West Virginia and Ohio for more than seven decades, is selling its business amid ongoing financial strain from reduced payments by pharmacy benefit managers. The sale underscores how declining reimbursements are forcing many community pharmacies to close or consolidate, with Fruth leadership calling on lawmakers to hold PBMs accountable before more independents disappear. Walgreens gains additional regional presence as it continues pursuing a broader health and beauty strategy, even as it faces its own profit pressures from shrinking pharmacy margins and intensified competition from dollar stores and e-commerce rivals. (Link)

Venture and Other News

1. Sorcero secures $42.5 million Series B led by NewSpring Capital, with Leawood Venture Capital, NZVC, First Trust Capital Partners, Koru Capital and Blu Ventures backing Agentic AI expansion across life sciences

   The funding will scale Sorcero's medically tuned intelligence platform, which already serves one-third of the top 30 global pharma companies and delivers dramatically faster insight generation for medical affairs, safety, scientific communications, and medtech teams. By unifying hundreds of global data sources on more than 40 million HCPs and 100 million scientists, the platform provides highly accurate, compliant real-world evidence that improves scientific publishing speed, precision targeting, and therapy adoption. Strategic partnerships with Google Cloud, Springer Nature, ServiceNow, USDM Life Sciences, and Snowflake underpin Sorcero's regulated, global growth. (Link)

2. Evidium raises $22M Series A, backed by Health2047, WGG Partners, the American Medical Association, Interwoven Ventures, Mindset Ventures, Perplexity and Innovaccer to scale its transparent healthcare AI platform

   The funding will accelerate Evidium's product development, enhance its clinical and cost modelling, and expand go-to-market efforts with health plans and provider organizations. The company's AI platform converts medical knowledge into transparent, traceable reasoning to support clinicians, insurers, and health systems with precision forecasting and quality insights. Evidium will make strategic hires in AI research, clinical science, and business roles to meet demand for tools that clarify patient journeys and predict outcomes and costs. Its precision-first products aim to break down data silos, provide non–black-box insights, and augment existing tools with clinically grounded logic. (Link)

3. Zetagen Therapeutics raises $12.9 million Series B1 led by JSTAR Capital Investments to advance breast cancer therapies

   Investor demand was strong for Zetagen's proprietary intratumoral platform addressing primary and metastatic breast cancer, with funds used to commercialize ZetaMet for bone metastases and accelerate clinical development of ZetaMast for liver metastases, as well as supporting preclinical studies and manufacturing for ZetaPrime targeting HR+ breast cancer. Phase 2a data for ZetaMet from the University of British Columbia showed complete response in lesions and full bone regeneration, with results to be presented at SABCS 2025. The company now holds 70+ patents, expanding its global intellectual property. (Link)